Cargando…

OR03-1 Achievement of HbA1c <6.5% without weight gain and hypoglycemia in people with type 2 diabetes treated with tirzepatide across the phase 3 SURPASS program

INTRODUCTION: Tirzepatide, the novel dual GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes, has been shown to reduce HbA1c and weight, with more patients achieving HbA1c ≤6.5%, compared to placebo and active comparators in the phase 3 SURPASS 1-5 studies. This analysis compared the pe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Allen, Sheryl Elaine, Cheng, Alice, Choudhary, Pratik, Levine, Joshua A, Ranta, Kari, Thieu, Vivian Thuyanh, Valderas, Elisa Gomez, Lingvay, Ildiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Diabetes & Glucose Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624730/ http://dx.doi.org/10.1210/jendso/bvac150.722

Ejemplares similares

Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme
por: Boye, Kristina S., et al.
Publicado: (2023)

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program
por: Lingvay, Ildiko, et al.
Publicado: (2023)

OR28-4 Efficacy and Safety of Tirzepatide Versus Semaglutide in a Hispanic or Latino Population: A Prespecified Subgroup Analysis of SURPASS-2
por: Benneyworth, Brian D, et al.
Publicado: (2022)

THU296 Effect Of Tirzepatide In GADA-positive Individuals With T2D: A Post Hoc Analysis Of The SURPASS 2-5 Trials
por: Peters, Anne L, et al.
Publicado: (2023)

FRI612 Tirzepatide For The Treatment Of Post-bariatric Surgery Hypoglycemia And Early Dumping Syndrome
por: Frederick Stortz, Ethan, et al.
Publicado: (2023)

Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials
por: Rosenstock, Julio, et al.
Publicado: (2023)

Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1)
por: Lee, Clare J, et al.
Publicado: (2023)

The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
por: Jung, Han Na, et al.
Publicado: (2022)

Generalizability of the SURPASS‐2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control
por: Chiu, Nicholas, et al.
Publicado: (2022)

Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide
por: Boye, Kristina S., et al.
Publicado: (2023)

ODP169 Challenges with use of HbA1C for Evaluation of Blood Glucose Control
por: Maletkovic, Jelena
Publicado: (2022)

THU253 The Hemoglobin Wayne Variant And Association With Falsely Elevated HbA1c
por: Mulpuri, Neha, et al.
Publicado: (2023)

MON-168 Hypoglycemia in Diabetics 65 Years and Older in Africans and Ademolus Classification of Hypoglycemia
por: Ademolu, Adegbenga
Publicado: (2019)

PSUN317 IL-3 is associated with HbA1c and Serum Lipids in African Americans
por: Wamble, Ezekial, et al.
Publicado: (2022)

THU322 Lower HbA1c Is Associated With Lower In-Hospital Mortality In Patients With COVID-19
por: Tsikala Vafea, Maria, et al.
Publicado: (2023)

Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3
por: Viljoen, Adie, et al.
Publicado: (2023)

FRI643 Tirzepatide Associated Partial Small Bowel Obstruction: A Case Report
por: Mathew, Anoopa, et al.
Publicado: (2023)

SAT152 Retrospective Analysis Of HbA1c In Patients Diagnosed With Pancreatic Insulinoma Prior To- And After Surgical Excision
por: Lawless, Sarah Jean, et al.
Publicado: (2023)

MON-153 Spurious High HbA1c: Do We Need to Review the Guidelines?
por: Eid, Hatem
Publicado: (2019)

MON-LB025 An Artificially Low HbA1c as a Result of Dapsone Therapy
por: George, Robert, et al.
Publicado: (2019)

ODP237 Relation Between Long Term Glycemic Variability (LTGV) and HbA1c Time-In-Range in Diabetic Patients.
por: Delgado-Vazquez, Angel Jesus, et al.
Publicado: (2022)

PSUN300 The sex-specific correlation of IL7, high HbA1c and liver damage markers in African Americans
por: Webb, Kenisha, et al.
Publicado: (2022)

OR03-4 Efficacy and Safety of Avexitide for Treatment of Hypoglycemia after Gastrointestinal Surgery; Assessment of Novel Dosing Regimens in an Expanded Indication
por: Craig, Colleen, et al.
Publicado: (2022)

ODP163 Association of HbA1c and Comfort with Diabetes Self-Management Among Adolescents and Young Adults with Type 1 Diabetes
por: Onwukwe, Obichi, et al.
Publicado: (2022)

PSUN189 Psychological Treatment for Diabetes Distress is Associated with Reduction in HbA1c, Emergency Department Presentations and Improvement in Psychological Health.
por: Calderwood, Clare, et al.
Publicado: (2022)

THU266 Lowered HbA1c In Individuals With Long-term Type 1 Diabetes Undergoing BCG Bladder Cancer Therapy
por: Dias, Hans, et al.
Publicado: (2023)

The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
por: Min, Thinzar, et al.
Publicado: (2020)

THU255 Tirzepatide-induced Weight Loss In A Type 2 Diabetic Taking Oral Contraceptives
por: Arunachalam, Amar, et al.
Publicado: (2023)

MON-625 Utility of Continuous Glucose Monitoring in Children with Type 1 Diabetes: Is HbA1c Enough?
por: Owens, Lindsey L, et al.
Publicado: (2020)

ODP211 Impact of Race and Chronic Kidney Disease on the Correlation between HbA1c and Continuous Glucose Monitoring (CGM) Glycemic Measures
por: Kaplan, Leah, et al.
Publicado: (2022)

Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis
por: Heerspink, Hiddo J.L., et al.
Publicado: (2023)

Normalization of HbA1c Following an Ad-Libitum, Non-Ketogenic Low Carbohydrate Diet Along With Antidiabetic Agents
por: Torbay, Naji, et al.
Publicado: (2021)

THU288 An Analysis Of The Association Between Age, HbA1c, Central Corneal Thickness, And Lens Thickness Using Swept-source Optical Coherence Tomography
por: Borkhetaria, Rucha K, et al.
Publicado: (2023)

OR34-03 Defining Clinical Characteristics Of Patients With Severe Hypoglycemia After Roux-en-Y Gastric Bypass: How Do They Differ From Asymptomatic Patients?
por: Grover, Ashna, et al.
Publicado: (2023)

Definition of Norma / Prediabetes Cut-off Point for Fasting Glycaemia on the Basis of Glucose Tolerance Test and HbA1c Interrelationships
por: Ismayilova, Sevil, et al.
Publicado: (2021)

SAT099 Should We Use HbA1c Or Continuous Glucose Monitoring (CGM) For Treatment Adjustment In Type 2 Diabetes Non-insulin Treated Patients?
por: Totomirova, Tzvetelina, et al.
Publicado: (2023)

HbA(1c) and Risk of Severe Hypoglycemia in Type 2 Diabetes: The Diabetes and Aging Study
por: Lipska, Kasia J., et al.
Publicado: (2013)

SUN-152 De-Intensifying Diabetic Medications in Patients with Stable HbA1c: A National Survey of Primary Care Physicians and Endocrinologists
por: Ahmad, Sara, et al.
Publicado: (2019)

SAT-126 The Relationship of Continuous Glucose Monitoring (CGM)-Derived Time-in-Range (TIR) to Hemoglobin A1c (HbA1c)
por: Vigersky, Robert, et al.
Publicado: (2019)

Proportion of Patients With HbA1c Corresponding to Prediabetes and Diabetes Ranges Without Previous Diagnosis in a Covid-19 Unit in Mexico City
por: Aguilar-Soto, Mercedes, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uoq4n357etmnq843lvtvrlau4d